42409-58-5

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-3-methoxypyridin-2-amine is used as an intermediate in the synthesis of various drugs. Its chemical properties allow it to be a key component in the development of new pharmaceutical compounds, contributing to the creation of innovative treatments and medications.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Bromo-3-methoxypyridin-2-amine serves as an intermediate for the production of pesticides. Its unique structure and reactivity enable the development of effective pest control solutions, enhancing crop protection and contributing to increased agricultural productivity.
Used in Research and Development:
5-Bromo-3-methoxypyridin-2-amine is utilized in research and development for the exploration of new chemical compounds. Its distinctive attributes make it a promising candidate for the discovery of novel substances with potential applications in various fields, including medicine, agriculture, and materials science.

InChI:InChI=1/C6H7BrN2O/c1-10-5-2-4(7)3-9-6(5)8/h2-3H,1H3,(H2,8,9)

Upstream product

• 856850-22-1 5-bromo-3-methoxy-2-nitro-pyridine-1-oxide 
• 625-92-3 3,5-dibromopyridine 
• 78156-39-5 3-bromo-5-methoxypyridine 1-oxide 
• 152684-26-9 5-bromo-3-methoxy-2-nitropyridine 
• 50720-12-2 3-bromo-5-methoxypyridine 
• 54231-35-5 3-fuoro-2-nitropyridine 
• 20265-37-6 3-methoxy-2-nitropyridine 
• 10201-71-5 3-methoxypyridin-2-amine 

Downstream Products

• 947249-19-6 3-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxoborolan-2-yl)pyridine-2-amine 
• 52605-98-8 5-bromo-2,3-dimethoxypyridine 
• 1171919-88-2 2,3-dimethoxy-5-[(trimethylsilyl)ethynyl]pyridine 
• 1188301-82-7 5-(2-(4-fluorophenyl)oxazol-4-yl)-3-methoxypyridin-2-amine 
• 1188301-84-9 5-(5-bromo-2-(4-fluorophenyl)oxazol-4-yl)-3-methoxypyridin-2-amine 
• 1188298-68-1 5-(2-(4-fluorophenyl)-5-(pyridin-4-yl)oxazol-4-yl)-3-methoxypyridin-2-amine 
• 1188301-90-7 5-(2-(4-fluorophenyl)thiazol-4-yl)-3-methoxypyridin-2-amine 
• 1188301-91-8 5-(5-bromo-2-(4-fluorophenyl)thiazol-4-yl)-3-methoxypyridin-2-amine 
• 2171029-30-2 6-bromo-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine 
• 1516750-51-8 ethyl 6-bromo-8-methoxyimidazo[1,2-a]pyridine-2-carboxylate 
• 1450019-01-8 2-(4-(4-(6-amino-5-methoxypyridin-3-yl)-2-phenyl-1H-imidazol-5-yl)pyrimidin-2-ylamino)ethanol trifluroacetate 
• 1450018-76-4 3-methoxy-5-(5-(pyridine-4-yl)-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)pyridin-2-amine trifluoroacetate 
• 1188301-65-6 5-(5-bromo-2-(4-trifluoromethyl)phenyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)-3-methoxypyridin-2-amine 
• 1450018-72-0 3-methoxy-5-(2-phenyl-5-(pyridine-4-yl)-1H-imidazol-4-yl)pyridine-2-amine 

Relevant academic research and scientific papers

Directing Group Enables Electrochemical Selectively Meta-Bromination of Pyridines under Mild Conditions

Without the use of catalysts and oxidants, a facile and sustainable electrochemical bromination protocol was developed. By introducing the directing groups, the regioselectivity of pyridine derivatives could be controlled at themeta-position utilizing the inexpensive and safe bromine salts at room temperature. A variety of brominated pyridine derivatives were obtained in 28-95% yields, and the reaction could be readily performed at a gram scale. By combining the installation and removing the directing group, the concept ofmeta-bromination of pyridines could be verified.

INDOLIN-2-ONE DERIVATIVES FOR USE IN THE TREATMENT OF CNS AND RELATED DISORDERS

The present invention is concerned with indolin-2-one derivatives of general formula (I) wherein A is phenyl or a six membered heteroaryl group, containing one or two N atoms, selected from or the oxygen atom may form together with two neighboring carbon atoms from the group A an additional fused ring, selected from or; R1 is hydrogen, lower alkyl, lower alkyl substitututed by halogen or oxetanyl; R2 is hydrogen, lower alkyl lower alkoxy, halogen or cycloalkyl; the dotted line is nothing or may be –CH2-; as well as with a pharmaceutically acceptable salt thereof, with a racemic mixture, or with its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive- compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, Huntington's disease, ADHD, amyotrophic lateral sclerosis, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems, epilepsy and neurodevelopmental disorders with co morbid epilepsy.

NOVEL COMPOUNDS FOR MODULATION OF ROR-GAMMA ACTIVITY

The present invention relates to aryl sulfones and related compounds that are modulators of ROR-gamma receptors. The invention also provides pharmaceutical compositions comprising these modulators, and methods of modulating ROR-gamma receptors using them. Also provided are methods of using aryl sulfones and related compounds as modulators of ROR-gamma to treat ROR-gamma mediated diseases

N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS

A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.

Novel Heterocyclic Compounds and Uses Thereof

New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

An efficient, regioselective amination of 3,5-disubstituted pyridine N-oxides using saccharin as an ammonium surrogate

A process for the regioselective amination of unsymmetrical 3,5-substituted pyridine N-oxides has been developed utilizing cheap, readily available saccharin as an ammonium surrogate. High conversions of the corresponding saccharin adducts have been achieved under mild reaction conditions. In situ deprotection under acidic conditions allows for a one-pot process to substituted aminopyridines. High regioselectivities were obtained from a variety of 3,5-disubstituted pyridine N-oxides.

PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE

The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of variou

BIARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are compounds for treatment of KIT, CSF-1R and/or FLT3 kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

DISUBSTITUTED IMIDAZOLE DERIVATIVES AS MODULATORS OF RAF KINASE

Novel substituted imidazole compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with an additional agent f

TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE

The present invention relates to compounds (I) useful as inhibitors of PBK, particularly of PI3K gamma. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders